



Resource impact template

Resource impact

Published: 22 November 2023

Last updated: 22 November 2023

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for chronic lymphocytic leukaemia:

- [Zanubrutinib for treating chronic lymphocytic leukaemia](#) (2023) NICE technology appraisal guidance 931
- [Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia](#) (2023) NICE technology appraisal guidance 891
- [Acalabrutinib for treating chronic lymphocytic leukaemia](#) (2021) NICE technology appraisal guidance 689
- [Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia](#) (2020) NICE technology appraisal guidance 663
- [Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia](#) (2019) NICE technology appraisal guidance 561
- [Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation](#) (2017) NICE technology appraisal guidance 429

